InterMune Inc. reported top-line results from a Phase III trial of Actimmune in the treatment of idiopathic pulmonary fibrosis that, while failing to meet its primary endpoint of progression-free survival, showed a survival benefit. (Bioworld Today)

InterMune Inc. reported top-line results from a Phase III trial of Actimmune in the treatment of idiopathic pulmonary fibrosis that, while failing to meet its primary endpoint of progression-free survival, showed a survival benefit. (Bioworld Today)